WORCESTER, Mass., July 15, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) ( www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that one of its proprietary confectionary over-the-counter products, Glucose RapidSpray™, is now available under a trial run at selected Boots UK ( www.Boots-UK.com) retail chain stores. Boots is a member of Alliance Boots ( www.allianceboots.com) and has approximately 2600 stores, from local community pharmacies to large destination health and beauty stores. Alliance Boots is a leading international, pharmacy-led health and beauty group delivering a range of products and services to customers. Glucose RapidSpray™ ( www.GlucoseRapidSpray.com) is a proprietary, innovative alternative for people who require or want additional glucose. Glucose RapidSpray™ delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray™ delivers glucose directly into the mouth where it is absorbed. Glucose RapidSpray™ is simple to carry and use with no large tablets to chew or messy gels to swallow. Presently, Glucose RapidSpray™ is available in retail pharmacies across Canada, the United States and in independent stores and pharmacies in the Middle East. The processes for registering the product for retail marketing in other countries is underway. Glucose RapidSpray™ was introduced to Boots UK through the Boots Centre for Innovation ( www.BootsInnovation.com). Established in 2007, Boots Centre for Innovation has been set up to work closely with early stage companies or inventors to develop pioneering products for the shelves of Alliance Boot stores. Boots Centre for Innovation is a not-for-profit partnership between Alliance Boots, Longbow Capital and The Institute of Life Science at Swansea University. "We welcome the opportunity to have our proprietary product, Glucose RapidSpray™, become available in the UK," said Rose C. Perri, Generex's Chief Operating Officer. "We remain confident that customers of this confectionary over-the-counter product will be satisfied with its results."
About Generex Biotechnology CorporationGenerex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com. The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831 Safe Harbor Statement This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: American Capital Ventures, Inc. Investor Relations Contact: Howard Gostfrand 1-877-918-0774 Beckerman Public Relations Media Contact: Christina Brozek 201-465-8002